{"product_id":"lly-business-model-canvas","title":"Eli Lilly and Company (LLY): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas gives you a practical, research-based view of how Eli Lilly and Company creates and captures value through high-value metabolic and neurology R\u0026amp;D, late-stage trials, manufacturing scale-up, and a 48,000-employee global workforce, supported by partnerships with CVS Caremark, telehealth providers, retail pharmacy networks, Medicare Part D and Medicare Bridge programs, and acquired biotech and vaccine developers. You'll see how LillyDirect, pharmacies, telehealth, and specialist channels serve adults with obesity or overweight, type 2 diabetes, obstructive sleep apnea with obesity, Alzheimer's patients and caregivers, and oncology patients, while revenue flows from product sales and costs are driven by R\u0026amp;D, manufacturing expansion, acquisitions, SG\u0026amp;A, launches, and litigation defense.\u003c\/p\u003e\u003ch2\u003eEli Lilly and Company - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\u003cp\u003eEli Lilly and Company's partnership layer is built around access, dispensing, and pipeline expansion. The most visible dollar amounts in this layer are \u003cstrong\u003e$399\u003c\/strong\u003e, \u003cstrong\u003e$549\u003c\/strong\u003e, \u003cstrong\u003e$590\u003c\/strong\u003e, \u003cstrong\u003e$2,000\u003c\/strong\u003e, \u003cstrong\u003e$610 million\u003c\/strong\u003e, \u003cstrong\u003e$1.04 billion\u003c\/strong\u003e, \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e, \u003cstrong\u003e$1.925 billion\u003c\/strong\u003e, and \u003cstrong\u003e$3.2 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner layer\u003c\/td\u003e\n\u003ctd\u003eReal-life example\u003c\/td\u003e\n\u003ctd\u003eKey numbers\u003c\/td\u003e\n\u003ctd\u003eBusiness role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCVS Caremark preferred coverage\u003c\/td\u003e\n\u003ctd\u003eZepbound, Mounjaro\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$399\u003c\/strong\u003e, \u003cstrong\u003e$549\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eFormulary access and lower patient cash-pay pressure\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndependent telehealth providers\u003c\/td\u003e\n\u003ctd\u003eLillyDirect\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e, \u003cstrong\u003e$399\u003c\/strong\u003e, \u003cstrong\u003e$549\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eDirect diagnosis-to-prescription path\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail pharmacy networks\u003c\/td\u003e\n\u003ctd\u003eCVS Pharmacy, Walgreens, Walmart\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eAbout 9,000\u003c\/strong\u003e, \u003cstrong\u003eabout 8,500\u003c\/strong\u003e, \u003cstrong\u003eabout 4,600\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003ePrescription fill and refill capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare Part D and Medicare Bridge programs\u003c\/td\u003e\n \u003ctd\u003ePart D coverage channel\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$590\u003c\/strong\u003e, \u003cstrong\u003e$2,000\u003c\/strong\u003e, \u003cstrong\u003eabout 53 million\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003ePublic insurance access and temporary bridge coverage\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquired biotech and vaccine developers\u003c\/td\u003e\n\u003ctd\u003eAkouos, Prevail Therapeutics, Versanis Bio, POINT Biopharma, Morphic Holding\u003c\/td\u003e\n \u003ctd\u003e\n\u003cstrong\u003e$610 million\u003c\/strong\u003e, \u003cstrong\u003e$1.04 billion\u003c\/strong\u003e, \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e, \u003cstrong\u003e$1.925 billion\u003c\/strong\u003e, \u003cstrong\u003e$3.2 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003ePipeline expansion and future revenue creation\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCVS Caremark preferred coverage\u003c\/strong\u003e shapes access to Lilly medicines when a PBM decides whether a drug sits in a preferred position on a formulary. For high-demand drugs, the difference between covered access and cash pay can be \u003cstrong\u003e$399\u003c\/strong\u003e a month for the 2.5 mg Zepbound vial and \u003cstrong\u003e$549\u003c\/strong\u003e a month for the 5 mg vial through LillyDirect.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$399\u003c\/strong\u003e monthly self-pay price for the 2.5 mg Zepbound vial.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$549\u003c\/strong\u003e monthly self-pay price for the 5 mg Zepbound vial.\u003c\/li\u003e\n \u003cli\u003ePreferred coverage reduces the need for patients to move to cash-pay channels.\u003c\/li\u003e\n \u003cli\u003ePreferred formulary status matters most for chronic drugs with monthly refills.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eIndependent telehealth providers\u003c\/strong\u003e connect diagnosis, prescribing, and fulfillment. LillyDirect launched in \u003cstrong\u003e2024\u003c\/strong\u003e, and the self-pay vial pathway turned telehealth into a direct access route for obesity treatment at \u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e per month for the starter and 5 mg vial doses.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e LillyDirect launch year.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e monthly vial prices tied to direct access.\u003c\/li\u003e\n \u003cli\u003eTelehealth reduces the gap between screening and first fill.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRetail pharmacy networks\u003c\/strong\u003e remain the last-mile partner for scale. Lilly medicines need high-volume dispensing points, and the major U.S. chains provide that reach: CVS Pharmacy at \u003cstrong\u003eabout 9,000\u003c\/strong\u003e locations, Walgreens at \u003cstrong\u003eabout 8,500\u003c\/strong\u003e, and Walmart at \u003cstrong\u003eabout 4,600\u003c\/strong\u003e U.S. stores.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCVS Pharmacy: \u003cstrong\u003eabout 9,000\u003c\/strong\u003e U.S. locations.\u003c\/li\u003e\n \u003cli\u003eWalgreens: \u003cstrong\u003eabout 8,500\u003c\/strong\u003e U.S. locations.\u003c\/li\u003e\n \u003cli\u003eWalmart: \u003cstrong\u003eabout 4,600\u003c\/strong\u003e U.S. stores.\u003c\/li\u003e\n \u003cli\u003eLarge networks matter because chronic drugs depend on repeat fills.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMedicare Part D and Medicare Bridge programs\u003c\/strong\u003e matter because public coverage rules determine who can stay on therapy after the first prescription. In \u003cstrong\u003e2025\u003c\/strong\u003e, the Part D deductible maximum is \u003cstrong\u003e$590\u003c\/strong\u003e, the annual out-of-pocket cap is \u003cstrong\u003e$2,000\u003c\/strong\u003e, and the market covers \u003cstrong\u003eabout 53 million\u003c\/strong\u003e beneficiaries.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$590\u003c\/strong\u003e 2025 Part D deductible maximum.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$2,000\u003c\/strong\u003e 2025 annual Part D out-of-pocket cap.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003eAbout 53 million\u003c\/strong\u003e Part D beneficiaries.\u003c\/li\u003e\n \u003cli\u003eBridge programs fill temporary access gaps while coverage is unresolved.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcquired biotech and vaccine developers\u003c\/strong\u003e expand Lilly's pipeline with large, upfront cash commitments. The disclosed deal values in this partnership layer include \u003cstrong\u003e$610 million\u003c\/strong\u003e for Akouos, \u003cstrong\u003e$1.04 billion\u003c\/strong\u003e for Prevail Therapeutics, \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e for POINT Biopharma, \u003cstrong\u003e$1.925 billion\u003c\/strong\u003e for Versanis Bio, and \u003cstrong\u003e$3.2 billion\u003c\/strong\u003e for Morphic Holding.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAkouos: \u003cstrong\u003e$610 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003ePrevail Therapeutics: \u003cstrong\u003e$1.04 billion\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003ePOINT Biopharma: \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003eVersanis Bio: \u003cstrong\u003e$1.925 billion\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003eMorphic Holding: \u003cstrong\u003e$3.2 billion\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003eThese deals turn outside science into internal revenue potential.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eEli Lilly and Company - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e of 2024 revenue depended on 2 core science areas: metabolic disease and neurology. The operating model rests on 5 linked activities: R\u0026amp;D, late-stage trials, regulatory approvals and launches, manufacturing scale-up, and IP defense.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey activity\u003c\/th\u003e\n\u003cth\u003eReal-life Lilly example\u003c\/th\u003e\n\u003cth\u003eNumbers and dates\u003c\/th\u003e\n\u003cth\u003eBusiness role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetabolic and neurology R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eTirzepatide and donanemab\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e 2024 revenue; \u003cstrong\u003e2\u003c\/strong\u003e core therapeutic areas; approvals in \u003cstrong\u003e2022\u003c\/strong\u003e, \u003cstrong\u003e2023\u003c\/strong\u003e, and \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTurns research output into commercial products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-stage clinical trials\u003c\/td\u003e\n\u003ctd\u003eSURMOUNT-1 and TRAILBLAZER-ALZ 2\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,539\u003c\/strong\u003e participants; \u003cstrong\u003e1,736\u003c\/strong\u003e participants; \u003cstrong\u003e72\u003c\/strong\u003e weeks; \u003cstrong\u003e18\u003c\/strong\u003e months; \u003cstrong\u003e4\u003c\/strong\u003e SURMOUNT-1 arms\u003c\/td\u003e\n\u003ctd\u003eReduces launch risk and supports label expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory filings and launches\u003c\/td\u003e\n\u003ctd\u003eMounjaro, Zepbound, Kisunla\u003c\/td\u003e\n\u003ctd\u003eMay \u003cstrong\u003e13, 2022\u003c\/strong\u003e; November \u003cstrong\u003e8, 2023\u003c\/strong\u003e; July \u003cstrong\u003e2, 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eConverts trial data into FDA approvals and revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing scale-up\u003c\/td\u003e\n\u003ctd\u003eNew manufacturing site in Lebanon, Indiana\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5.3 billion\u003c\/strong\u003e announced in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSupports supply for injectable and specialty products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP enforcement and litigation defense\u003c\/td\u003e\n\u003ctd\u003eProtection of tirzepatide and donanemab exclusivity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e tirzepatide brands; \u003cstrong\u003e1\u003c\/strong\u003e neurology launch; \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e revenue base\u003c\/td\u003e\n\u003ctd\u003eProtects patent life, market access, and pricing power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eMetabolic and neurology R\u0026amp;D\u003c\/p\u003e\n\u003cp\u003eTirzepatide is a dual GIP and GLP-1 receptor agonist. Donanemab is a neurology asset aimed at early symptomatic Alzheimer's disease. Lilly's R\u0026amp;D concentration shows up in \u003cstrong\u003e3\u003c\/strong\u003e major milestones: Mounjaro on May \u003cstrong\u003e13, 2022\u003c\/strong\u003e, Zepbound on November \u003cstrong\u003e8, 2023\u003c\/strong\u003e, and Kisunla on July \u003cstrong\u003e2, 2024\u003c\/strong\u003e. That sequence shows a pipeline that can move from one molecule family into multiple approved products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e core areas: metabolic disease and neurology\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e product milestones in \u003cstrong\u003e2022\u003c\/strong\u003e, \u003cstrong\u003e2023\u003c\/strong\u003e, and \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e in 2024 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLate-stage clinical trials\u003c\/p\u003e\n\u003cp\u003eSURMOUNT-1 enrolled \u003cstrong\u003e2,539\u003c\/strong\u003e adults, ran for \u003cstrong\u003e72\u003c\/strong\u003e weeks, and tested \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, \u003cstrong\u003e15 mg\u003c\/strong\u003e, and placebo. The \u003cstrong\u003e15 mg\u003c\/strong\u003e arm produced \u003cstrong\u003e22.5%\u003c\/strong\u003e mean weight loss. TRAILBLAZER-ALZ 2 enrolled \u003cstrong\u003e1,736\u003c\/strong\u003e participants over \u003cstrong\u003e18\u003c\/strong\u003e months. Those trial sizes and timelines show why late-stage execution is a core activity, not a side task.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e2,539\u003c\/strong\u003e participants in SURMOUNT-1\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1,736\u003c\/strong\u003e participants in TRAILBLAZER-ALZ 2\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e72\u003c\/strong\u003e-week and \u003cstrong\u003e18\u003c\/strong\u003e-month study horizons\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e22.5%\u003c\/strong\u003e mean weight loss at the \u003cstrong\u003e15 mg\u003c\/strong\u003e dose in SURMOUNT-1\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eRegulatory filings and launches\u003c\/p\u003e\n\u003cp\u003eThe launch cadence is tight: Mounjaro on May \u003cstrong\u003e13, 2022\u003c\/strong\u003e, Zepbound on November \u003cstrong\u003e8, 2023\u003c\/strong\u003e, and Kisunla on July \u003cstrong\u003e2, 2024\u003c\/strong\u003e. That gives Lilly \u003cstrong\u003e3\u003c\/strong\u003e major FDA milestones in a little more than \u003cstrong\u003e2\u003c\/strong\u003e years. For a company with a \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e revenue base, every approval date matters because it converts trial work into commercial supply and reimbursement activity.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMay 13, 2022\u003c\/strong\u003e: Mounjaro approval\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNovember 8, 2023\u003c\/strong\u003e: Zepbound approval\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eJuly 2, 2024\u003c\/strong\u003e: Kisunla approval\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e major FDA approvals across \u003cstrong\u003e2022\u003c\/strong\u003e, \u003cstrong\u003e2023\u003c\/strong\u003e, and \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eManufacturing scale-up\u003c\/p\u003e\n\u003cp\u003eManufacturing is a capital-heavy activity for Lilly's injectable and specialty-drug model. In \u003cstrong\u003e2024\u003c\/strong\u003e, the company announced \u003cstrong\u003e$5.3 billion\u003c\/strong\u003e for a new manufacturing site in Lebanon, Indiana. That is the kind of investment needed when demand is tied to high-volume chronic-disease products and when supply continuity affects both launches and prescription fill rates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$5.3 billion\u003c\/strong\u003e announced in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e new manufacturing site in Lebanon, Indiana\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e high-volume metabolic brands behind the scale-up need\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eIP enforcement and litigation defense\u003c\/p\u003e\n\u003cp\u003eWhen \u003cstrong\u003e2\u003c\/strong\u003e tirzepatide brands and \u003cstrong\u003e1\u003c\/strong\u003e neurology launch sit behind \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e of annual revenue, IP defense becomes part of the operating model. The value of each protected year rises when a franchise is this large, because exclusivity affects both launch economics and the duration of peak sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e tirzepatide brands: Mounjaro and Zepbound\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e neurology brand: Kisunla\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e 2024 revenue base\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eEli Lilly and Company - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\u003cp\u003eEli Lilly and Company's late-2025 key resources are anchored by \u003cstrong\u003e$11.5 billion\u003c\/strong\u003e in Mounjaro revenue in 2024, \u003cstrong\u003e$4.9 billion\u003c\/strong\u003e in Zepbound revenue in 2024, \u003cstrong\u003e$50 billion+\u003c\/strong\u003e in U.S. manufacturing investment since \u003cstrong\u003e2020\u003c\/strong\u003e, and a \u003cstrong\u003e48,000\u003c\/strong\u003e-employee workforce.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003eReal-life number or amount\u003c\/th\u003e\n\u003cth\u003eLate-2025 role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMounjaro\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$11.5 billion\u003c\/strong\u003e revenue in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCore metabolic franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.9 billion\u003c\/strong\u003e revenue in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCore obesity franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKisunla\u003c\/td\u003e\n\u003ctd\u003eApproved in \u003cstrong\u003e2024\u003c\/strong\u003e; no separate revenue disclosed\u003c\/td\u003e\n\u003ctd\u003eAlzheimer's franchise asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetevmo\u003c\/td\u003e\n\u003ctd\u003eApproved in \u003cstrong\u003e2020\u003c\/strong\u003e; no separate revenue disclosed\u003c\/td\u003e\n\u003ctd\u003eOncology franchise asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLillyDirect\u003c\/td\u003e\n\u003ctd\u003eLaunched in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDirect patient access channel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal manufacturing network\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$50 billion+\u003c\/strong\u003e U.S. manufacturing investment since \u003cstrong\u003e2020\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSupply, scale, and launch capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI, digital twin, and zero-trust systems\u003c\/td\u003e\n\u003ctd\u003eNo public numeric disclosure\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D, manufacturing, and cybersecurity infrastructure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e48,000\u003c\/strong\u003e employees\u003c\/td\u003e\n\u003ctd\u003eScientific, manufacturing, and commercial execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eMounjaro\u003c\/strong\u003e is the largest named resource in this chapter because \u003cstrong\u003e$11.5 billion\u003c\/strong\u003e in 2024 revenue gives Eli Lilly and Company a very large cash-generating base. That scale matters because it funds more manufacturing, more research, and faster market expansion.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eZepbound\u003c\/strong\u003e added \u003cstrong\u003e$4.9 billion\u003c\/strong\u003e in 2024 revenue, which shows that one science platform can create two major commercial assets. For business model analysis, that lowers dependence on a single product and raises the value of the underlying discovery platform.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKisunla\u003c\/strong\u003e, approved in \u003cstrong\u003e2024\u003c\/strong\u003e, and \u003cstrong\u003eRetevmo\u003c\/strong\u003e, approved in \u003cstrong\u003e2020\u003c\/strong\u003e, widen the resource base beyond metabolic disease. They matter because they keep Eli Lilly and Company exposed to multiple therapeutic areas, not just diabetes and obesity.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLillyDirect\u003c\/strong\u003e, launched in \u003cstrong\u003e2024\u003c\/strong\u003e, is a digital channel resource. It matters because direct access can reduce friction in patient onboarding, prescription fulfillment, and follow-up care, which is critical when demand is large and access controls can slow conversion into sales.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e$50 billion+\u003c\/strong\u003e in U.S. manufacturing investment since \u003cstrong\u003e2020\u003c\/strong\u003e makes production capacity one of the company's most important resources. In a drug business, capacity is a strategic asset because shortages, delays, and supply constraints can limit revenue even when demand is strong.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e48,000\u003c\/strong\u003e employees support discovery, clinical development, regulatory work, manufacturing, quality control, and commercialization.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e is the key year for both Mounjaro and Zepbound revenue disclosure in this resource set.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2020\u003c\/strong\u003e and \u003cstrong\u003e2024\u003c\/strong\u003e are the key approval years for Retevmo and Kisunla.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e is also the launch year for LillyDirect.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eAI, digital twin, and zero-trust systems are supporting resources rather than standalone products. A digital twin is a virtual model of a plant or process, and zero-trust means every access request is checked instead of assumed safe, which matters when the company is running large-scale research, manufacturing, and data operations at the same time.\u003c\/p\u003e\u003ch2\u003eEli Lilly and Company - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e20.9%\u003c\/strong\u003e mean weight loss, \u003cstrong\u003e2.30%\u003c\/strong\u003e HbA1c reduction, \u003cstrong\u003e14.7%\u003c\/strong\u003e oral weight loss, \u003cstrong\u003e35%\u003c\/strong\u003e slower Alzheimer's decline, and \u003cstrong\u003e$399\u003c\/strong\u003e to \u003cstrong\u003e$549\u003c\/strong\u003e cash-pay vial pricing are the clearest numeric signals behind Eli Lilly and Company's value proposition.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue proposition\u003c\/td\u003e\n\u003ctd\u003eReal-life number\u003c\/td\u003e\n\u003ctd\u003eProgram or product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBest-in-class obesity efficacy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,539\u003c\/strong\u003e participants; \u003cstrong\u003e72\u003c\/strong\u003e weeks; \u003cstrong\u003e20.9%\u003c\/strong\u003e mean weight loss; \u003cstrong\u003e3.1%\u003c\/strong\u003e placebo\u003c\/td\u003e\n \u003ctd\u003eSURMOUNT-1; tirzepatide \u003cstrong\u003e15 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiabetes efficacy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e40\u003c\/strong\u003e weeks; \u003cstrong\u003e2.01%\u003c\/strong\u003e, \u003cstrong\u003e2.24%\u003c\/strong\u003e, and \u003cstrong\u003e2.30%\u003c\/strong\u003e HbA1c reduction; \u003cstrong\u003e1.86%\u003c\/strong\u003e comparator\u003c\/td\u003e\n \u003ctd\u003eSURPASS-2; tirzepatide \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e10 mg\u003c\/strong\u003e, and \u003cstrong\u003e15 mg\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral needle-free weight-loss option\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e36\u003c\/strong\u003e weeks; up to \u003cstrong\u003e14.7%\u003c\/strong\u003e weight loss\u003c\/td\u003e\n \u003ctd\u003eOrforglipron phase 2 obesity data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpanded treatment for sleep apnea and Alzheimer's\u003c\/td\u003e\n \u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e phase 3 sleep apnea trials; \u003cstrong\u003e76\u003c\/strong\u003e weeks; \u003cstrong\u003e35%\u003c\/strong\u003e slower decline; \u003cstrong\u003e22%\u003c\/strong\u003e overall\u003c\/td\u003e\n \u003ctd\u003eObstructive sleep apnea; donanemab in early symptomatic Alzheimer's disease\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConvenient direct access\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e launch; \u003cstrong\u003e$399\u003c\/strong\u003e; \u003cstrong\u003e$549\u003c\/strong\u003e\n\u003c\/td\u003e\n \u003ctd\u003eLillyDirect cash-pay vial pricing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReliable high-volume supply\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2.5 billion\u003c\/strong\u003e; \u003cstrong\u003e$5.3 billion\u003c\/strong\u003e; \u003cstrong\u003e$7.8 billion\u003c\/strong\u003e combined\u003c\/td\u003e\n \u003ctd\u003eManufacturing investment announcements\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eBest-in-class obesity and diabetes efficacy\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTirzepatide gives Eli Lilly and Company a measurable edge in both obesity and type 2 diabetes. In SURMOUNT-1, \u003cstrong\u003e2,539\u003c\/strong\u003e adults were treated for \u003cstrong\u003e72\u003c\/strong\u003e weeks, and the \u003cstrong\u003e15 mg\u003c\/strong\u003e dose produced \u003cstrong\u003e20.9%\u003c\/strong\u003e mean weight loss versus \u003cstrong\u003e3.1%\u003c\/strong\u003e with placebo. In SURPASS-2, the same molecule reduced HbA1c by \u003cstrong\u003e2.01%\u003c\/strong\u003e at \u003cstrong\u003e5 mg\u003c\/strong\u003e, \u003cstrong\u003e2.24%\u003c\/strong\u003e at \u003cstrong\u003e10 mg\u003c\/strong\u003e, and \u003cstrong\u003e2.30%\u003c\/strong\u003e at \u003cstrong\u003e15 mg\u003c\/strong\u003e, compared with \u003cstrong\u003e1.86%\u003c\/strong\u003e for the active comparator.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2,539\u003c\/strong\u003e participants in SURMOUNT-1.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e72\u003c\/strong\u003e weeks in SURMOUNT-1.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e20.9%\u003c\/strong\u003e mean weight loss at \u003cstrong\u003e15 mg\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e3.1%\u003c\/strong\u003e placebo weight loss.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e40\u003c\/strong\u003e weeks in SURPASS-2.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2.30%\u003c\/strong\u003e HbA1c reduction at \u003cstrong\u003e15 mg\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e1.86%\u003c\/strong\u003e comparator HbA1c reduction.\u003c\/li\u003e\n \u003cli\u003eWeight-management eligibility: BMI \u003cstrong\u003e30\u003c\/strong\u003e or higher, or BMI \u003cstrong\u003e27\u003c\/strong\u003e to \u003cstrong\u003e29.9\u003c\/strong\u003e with at least one weight-related condition.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOral needle-free weight-loss option\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eOrforglipron gives Eli Lilly and Company an oral, once-daily option instead of an injection. Phase 2 obesity data showed up to \u003cstrong\u003e14.7%\u003c\/strong\u003e weight loss at \u003cstrong\u003e36\u003c\/strong\u003e weeks, which supports a lower-friction treatment path for patients who want a tablet-based option.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e oral tablet taken once daily.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e14.7%\u003c\/strong\u003e maximum reported weight loss.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e36\u003c\/strong\u003e weeks of phase 2 data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eExpanded treatment for sleep apnea and Alzheimer's\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe value proposition expands when obesity treatment also reaches obstructive sleep apnea and early symptomatic Alzheimer's disease. Eli Lilly and Company's sleep apnea program includes \u003cstrong\u003e2\u003c\/strong\u003e phase 3 trials, and donanemab is dosed every \u003cstrong\u003e4\u003c\/strong\u003e weeks. In the Alzheimer's program, the reported slowing of decline was \u003cstrong\u003e35%\u003c\/strong\u003e in the low\/medium-tau group and \u003cstrong\u003e22%\u003c\/strong\u003e in the overall population over \u003cstrong\u003e76\u003c\/strong\u003e weeks.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e phase 3 sleep apnea trials.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e-week dosing interval for donanemab.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e76\u003c\/strong\u003e weeks in the Alzheimer's readout.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e35%\u003c\/strong\u003e slower decline in the low\/medium-tau group.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e22%\u003c\/strong\u003e slower decline in the overall population.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eReliable high-volume supply\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSupply is part of the value proposition because the obesity and diabetes franchises depend on volume, not only efficacy. Eli Lilly and Company announced manufacturing investments of \u003cstrong\u003e$2.5 billion\u003c\/strong\u003e and \u003cstrong\u003e$5.3 billion\u003c\/strong\u003e, for \u003cstrong\u003e$7.8 billion\u003c\/strong\u003e combined.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.5 billion\u003c\/strong\u003e manufacturing investment announcement.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$5.3 billion\u003c\/strong\u003e manufacturing investment announcement.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$7.8 billion\u003c\/strong\u003e combined amount.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eConvenient direct access through LillyDirect\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLillyDirect gives Eli Lilly and Company a direct cash-pay route to patients. The published vial prices were \u003cstrong\u003e$399\u003c\/strong\u003e for \u003cstrong\u003e2.5 mg\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e for \u003cstrong\u003e5 mg\u003c\/strong\u003e, with the launch in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$399\u003c\/strong\u003e monthly vial price for \u003cstrong\u003e2.5 mg\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$549\u003c\/strong\u003e monthly vial price for \u003cstrong\u003e5 mg\u003c\/strong\u003e.\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e launch.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eEli Lilly and Company - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003eEli Lilly and Company's customer relationships in late 2025 are built around \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e in 2024 revenue, direct-to-patient access launched in \u003cstrong\u003e2024\u003c\/strong\u003e, insulin out-of-pocket caps of \u003cstrong\u003e$35\u003c\/strong\u003e per month, and Zepbound self-pay vial prices of \u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e. The model mixes self-service, payer access, pharmacy routing, and specialist prescribing.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelationship channel\u003c\/td\u003e\n\u003ctd\u003eReal-life numbers\u003c\/td\u003e\n\u003ctd\u003eCustomer relationship form\u003c\/td\u003e\n\u003ctd\u003eBusiness impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect-to-consumer self-service\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e launch; Zepbound self-pay vial prices of \u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDirect patient access through an online route\u003c\/td\u003e\n\u003ctd\u003eReduces friction for self-pay patients and repeat fills\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFormulary and payer access management\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e 2024 revenue; insulin list price cuts of up to \u003cstrong\u003e70%\u003c\/strong\u003e in \u003cstrong\u003e2023\u003c\/strong\u003e; monthly out-of-pocket cap of \u003cstrong\u003e$35\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eCoverage, rebates, and affordability programs\u003c\/td\u003e\n\u003ctd\u003eShapes whether patients pay cash, copay, or insurer-negotiated amounts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient support via telehealth and pharmacies\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e launch; \u003cstrong\u003e$35\u003c\/strong\u003e monthly insulin cap; \u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e self-pay Zepbound prices\u003c\/td\u003e\n\u003ctd\u003eTelehealth routing and pharmacy fulfillment\u003c\/td\u003e\n\u003ctd\u003eSupports access, refill continuity, and home delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist-led chronic disease treatment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e38.4 million\u003c\/strong\u003e people with diabetes; \u003cstrong\u003e42.4%\u003c\/strong\u003e of U.S. adults with obesity\u003c\/td\u003e\n\u003ctd\u003eSpecialist prescribing in long-duration diseases\u003c\/td\u003e\n\u003ctd\u003eCreates recurring relationships with patients and prescribers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect-to-consumer self-service\u003c\/strong\u003e is most visible in LillyDirect. The patient-facing route matters because chronic therapies are refill-driven, and the company has tied convenience to price with Zepbound self-pay vial prices of \u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e per month. The same affordability logic appears in insulin, where Lilly capped out-of-pocket costs at \u003cstrong\u003e$35\u003c\/strong\u003e per month and cut list prices by up to \u003cstrong\u003e70%\u003c\/strong\u003e in \u003cstrong\u003e2023\u003c\/strong\u003e. Those numbers matter because a lower entry price can keep patients on therapy longer.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFormulary and payer access management\u003c\/strong\u003e is the gatekeeper relationship. Commercial insurers, pharmacy benefit managers, Medicare, and Medicaid decide whether the patient pays cash or a plan-based amount. For a company that reported \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e in 2024 revenue, payer access is not a side task; it is part of the customer relationship. A drug priced at \u003cstrong\u003e$399\u003c\/strong\u003e or \u003cstrong\u003e$549\u003c\/strong\u003e for self-pay can still face very different access conditions when a plan covers it, restricts it, or asks for prior authorization.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePatient support via telehealth and pharmacies\u003c\/strong\u003e links prescribing, fulfillment, and payment. LillyDirect's model depends on digital entry, telehealth routing, and pharmacy fulfillment instead of a single office visit. That is useful for therapies that need ongoing monitoring and repeated refills. The measurable parts of this relationship are the \u003cstrong\u003e2024\u003c\/strong\u003e launch, the \u003cstrong\u003e$35\u003c\/strong\u003e monthly insulin cap, and the \u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e self-pay Zepbound vial prices. Those figures show that Lilly is managing both access and adherence at the same time.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialist-led chronic disease treatment\u003c\/strong\u003e is where Eli Lilly and Company's relationships become long term. In the U.S., \u003cstrong\u003e38.4 million\u003c\/strong\u003e people have diabetes and \u003cstrong\u003e42.4%\u003c\/strong\u003e of adults have obesity, so the customer base is large and recurring. Endocrinologists, obesity-medicine physicians, and other specialists hold much of the prescribing power, while patients stay on therapy for months or years. That makes the relationship less like a one-time sale and more like a repeated clinical and financial process.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$45.0 billion\u003c\/strong\u003e 2024 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e LillyDirect launch\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e Zepbound self-pay vial prices\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$35\u003c\/strong\u003e monthly insulin out-of-pocket cap\u003c\/li\u003e\n\u003cli\u003eUp to \u003cstrong\u003e70%\u003c\/strong\u003e insulin list price cuts in \u003cstrong\u003e2023\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e38.4 million\u003c\/strong\u003e people with diabetes in the U.S.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e42.4%\u003c\/strong\u003e U.S. adult obesity prevalence\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eEli Lilly and Company - Canvas Business Model: Channels\u003c\/h2\u003e\n\u003cp\u003eEli Lilly and Company uses a mixed channel model built around LillyDirect, retail pharmacies, traditional prescription dispensing, telehealth providers, and specialist or hospital settings. The clearest numeric markers are LillyDirect's \u003cstrong\u003e2024\u003c\/strong\u003e launch, Zepbound self-pay vial prices of \u003cstrong\u003e$399\u003c\/strong\u003e and \u003cstrong\u003e$549\u003c\/strong\u003e, and the Zepbound pen list price of \u003cstrong\u003e$1,059.87\u003c\/strong\u003e per \u003cstrong\u003e4 weeks\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eChannel\u003c\/td\u003e\n\u003ctd\u003eReal-life number or amount\u003c\/td\u003e\n\u003ctd\u003eChannel role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLillyDirect\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e; \u003cstrong\u003e$399\u003c\/strong\u003e; \u003cstrong\u003e$549\u003c\/strong\u003e; \u003cstrong\u003e$1,059.87\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDirect-to-patient access and self-pay routing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail pharmacies\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1,059.87\u003c\/strong\u003e per \u003cstrong\u003e4 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eStandard outpatient dispensing for branded prescriptions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTraditional prescription dispensing\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4 weeks\u003c\/strong\u003e supply cadence\u003c\/td\u003e\n\u003ctd\u003ePhysician-to-pharmacy fulfillment under insurance or cash pay\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTelehealth providers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e platform launch\u003c\/td\u003e\n\u003ctd\u003eOnline consult and prescription routing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist and hospital channels\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4 weeks\u003c\/strong\u003e between Kisunla infusions\u003c\/td\u003e\n\u003ctd\u003eSpecialist-office, infusion-center, and hospital administration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eLillyDirect\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLillyDirect launched in \u003cstrong\u003e2024\u003c\/strong\u003e. For Zepbound, the self-pay vial pathway has published prices of \u003cstrong\u003e$399\u003c\/strong\u003e for the \u003cstrong\u003e2.5 mg\u003c\/strong\u003e vial and \u003cstrong\u003e$549\u003c\/strong\u003e for the \u003cstrong\u003e5 mg\u003c\/strong\u003e vial. Against the Zepbound pen list price of \u003cstrong\u003e$1,059.87\u003c\/strong\u003e per \u003cstrong\u003e4 weeks\u003c\/strong\u003e, the vial prices are \u003cstrong\u003e$660.87\u003c\/strong\u003e lower and \u003cstrong\u003e$510.87\u003c\/strong\u003e lower, which is \u003cstrong\u003e62.4%\u003c\/strong\u003e and \u003cstrong\u003e48.2%\u003c\/strong\u003e below the pen list price.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e launch\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$399\u003c\/strong\u003e self-pay vial price\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$549\u003c\/strong\u003e self-pay vial price\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1,059.87\u003c\/strong\u003e pen list price\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e62.4%\u003c\/strong\u003e lower vs the pen list price\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e48.2%\u003c\/strong\u003e lower vs the pen list price\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRetail pharmacies\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRetail pharmacies are the main outpatient fill point for prescriptions that move through the standard insurance and pharmacy benefit flow. For Lilly, this matters most for branded medicines that patients pick up as a pharmacy claim rather than through a hospital or infusion center. The \u003cstrong\u003e$1,059.87\u003c\/strong\u003e Zepbound pen list price gives you a clear retail benchmark for a \u003cstrong\u003e4-week\u003c\/strong\u003e supply.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1,059.87\u003c\/strong\u003e retail list price benchmark\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e4 weeks\u003c\/strong\u003e supply basis\u003c\/li\u003e\n\u003cli\u003eOutpatient pharmacy claim\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eTraditional prescription dispensing\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis is the standard doctor-to-pharmacy route used for most Lilly outpatient medicines. The channel depends on a prescriber, a diagnosis, and pharmacy fulfillment, with refill timing often built around a \u003cstrong\u003e4-week\u003c\/strong\u003e supply cycle. It is the channel most exposed to copays, prior authorization, and pharmacy benefit rules.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e4 weeks\u003c\/strong\u003e supply cycle\u003c\/li\u003e\n\u003cli\u003ePrescriber-written prescription\u003c\/li\u003e\n\u003cli\u003ePharmacy fulfillment\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eTelehealth providers\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLillyDirect includes independent telehealth providers, so the access path can start online before the prescription is routed to a pharmacy or self-pay option. This matters in obesity care because the first clinical touchpoint can happen without an in-person visit.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e digital channel launch\u003c\/li\u003e\n\u003cli\u003eOnline consult\u003c\/li\u003e\n\u003cli\u003ePrescription routing\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialist and hospital channels\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSpecialist and hospital channels are critical for therapies that need clinician supervision or infusion. Kisunla is administered as an intravenous infusion every \u003cstrong\u003e4 weeks\u003c\/strong\u003e, so specialist offices, infusion centers, and hospital outpatient departments are part of the channel mix. That makes this channel structurally different from retail pharmacy dispensing.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e4 weeks\u003c\/strong\u003e between infusions\u003c\/li\u003e\n\u003cli\u003eSpecialist offices\u003c\/li\u003e\n\u003cli\u003eInfusion centers\u003c\/li\u003e\n\u003cli\u003eHospital outpatient departments\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eEli Lilly and Company - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e2.5 billion\u003c\/strong\u003e adults were overweight in 2022, and \u003cstrong\u003e890 million\u003c\/strong\u003e were living with obesity. The U.S. adult obesity prevalence was \u003cstrong\u003e41.9%\u003c\/strong\u003e in 2017-2020.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e537 million\u003c\/strong\u003e adults were living with diabetes in 2021, and about \u003cstrong\u003e90%\u003c\/strong\u003e to \u003cstrong\u003e95%\u003c\/strong\u003e of diabetes cases are type 2. The U.S. had \u003cstrong\u003e38.4 million\u003c\/strong\u003e people with diabetes.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e936 million\u003c\/strong\u003e adults aged 30-69 years were estimated to have obstructive sleep apnea worldwide, and \u003cstrong\u003e425 million\u003c\/strong\u003e had moderate-to-severe obstructive sleep apnea. The phase 3 SURMOUNT-OSA program enrolled \u003cstrong\u003e469\u003c\/strong\u003e adults with obesity and moderate-to-severe obstructive sleep apnea.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e55 million\u003c\/strong\u003e people were living with dementia worldwide, with \u003cstrong\u003e10 million\u003c\/strong\u003e new cases each year. In the United States, \u003cstrong\u003e6.9 million\u003c\/strong\u003e people age 65 and older were living with Alzheimer's in 2024, and \u003cstrong\u003e11.5 million\u003c\/strong\u003e unpaid caregivers were supporting people with Alzheimer's or other dementias.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e20 million\u003c\/strong\u003e new cancer cases were recorded worldwide in 2022, with \u003cstrong\u003e9.7 million\u003c\/strong\u003e deaths and \u003cstrong\u003e53.5 million\u003c\/strong\u003e people living within 5 years of a cancer diagnosis. Breast cancer accounted for \u003cstrong\u003e2.3 million\u003c\/strong\u003e new cases, lung cancer for \u003cstrong\u003e2.5 million\u003c\/strong\u003e, and colorectal cancer for \u003cstrong\u003e1.9 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer segment\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-world size\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eLate-2025 customer profile\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNumeric anchor\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdults with obesity or overweight\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.5 billion\u003c\/strong\u003e overweight adults; \u003cstrong\u003e890 million\u003c\/strong\u003e with obesity\u003c\/td\u003e\n\u003ctd\u003eChronic weight management\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e41.9%\u003c\/strong\u003e U.S. adult obesity prevalence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eType 2 diabetes patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e537 million\u003c\/strong\u003e adults with diabetes\u003c\/td\u003e\n\u003ctd\u003eLong-term glucose control\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e90%\u003c\/strong\u003e to \u003cstrong\u003e95%\u003c\/strong\u003e type 2; \u003cstrong\u003e38.4 million\u003c\/strong\u003e U.S. diabetes cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eObstructive sleep apnea patients with obesity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e936 million\u003c\/strong\u003e adults with OSA; \u003cstrong\u003e425 million\u003c\/strong\u003e moderate-to-severe\u003c\/td\u003e\n\u003ctd\u003eObesity-linked sleep-disorder treatment\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e469\u003c\/strong\u003e adults in SURMOUNT-OSA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlzheimer's patients and caregivers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e55 million\u003c\/strong\u003e people with dementia; \u003cstrong\u003e10 million\u003c\/strong\u003e new cases each year\u003c\/td\u003e\n\u003ctd\u003eEarly symptomatic Alzheimer's treatment and caregiver-mediated access\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6.9 million\u003c\/strong\u003e U.S. age 65+ with Alzheimer's; \u003cstrong\u003e11.5 million\u003c\/strong\u003e unpaid caregivers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20 million\u003c\/strong\u003e new cases in 2022; \u003cstrong\u003e9.7 million\u003c\/strong\u003e deaths\u003c\/td\u003e\n\u003ctd\u003eSolid tumors and hematologic cancers\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e53.5 million\u003c\/strong\u003e 5-year prevalence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003eBreast cancer: \u003cstrong\u003e2.3 million\u003c\/strong\u003e new cases in 2022\u003c\/li\u003e\n\u003cli\u003eLung cancer: \u003cstrong\u003e2.5 million\u003c\/strong\u003e new cases in 2022\u003c\/li\u003e\n\u003cli\u003eColorectal cancer: \u003cstrong\u003e1.9 million\u003c\/strong\u003e new cases in 2022\u003c\/li\u003e\n\u003cli\u003eAlzheimer's disease: \u003cstrong\u003e6.9 million\u003c\/strong\u003e U.S. patients age 65 and older in 2024\u003c\/li\u003e\n\u003cli\u003eCaregivers: \u003cstrong\u003e11.5 million\u003c\/strong\u003e unpaid caregivers in the United States\u003c\/li\u003e\n\u003cli\u003eObesity: \u003cstrong\u003e890 million\u003c\/strong\u003e people living with obesity worldwide\u003c\/li\u003e\n\u003cli\u003eType 2 diabetes: about \u003cstrong\u003e90%\u003c\/strong\u003e to \u003cstrong\u003e95%\u003c\/strong\u003e of diabetes cases\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eEli Lilly and Company - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$5.3B\u003c\/strong\u003e for Lebanon, Indiana and \u003cstrong\u003e$3.2B\u003c\/strong\u003e for Morphic are the clearest large cost signals in Eli Lilly and Company's recent structure.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eR\u0026amp;D and clinical trial spend\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eResearch and development expense was \u003cstrong\u003e$8.9B\u003c\/strong\u003e in 2023. Eli Lilly and Company's pipeline cost base also included acquisition-driven R\u0026amp;D spend of \u003cstrong\u003e$2.4B\u003c\/strong\u003e for DICE Therapeutics, \u003cstrong\u003e$1.93B\u003c\/strong\u003e for Versanis Bio, \u003cstrong\u003e$1.4B\u003c\/strong\u003e for POINT Biopharma Global, and \u003cstrong\u003e$309.6M\u003c\/strong\u003e for Sigilon Therapeutics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$8.9B\u003c\/strong\u003e research and development expense, 2023\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$2.4B\u003c\/strong\u003e DICE Therapeutics acquisition\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.93B\u003c\/strong\u003e Versanis Bio acquisition\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.4B\u003c\/strong\u003e POINT Biopharma Global acquisition\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$309.6M\u003c\/strong\u003e Sigilon Therapeutics acquisition\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eR\u0026amp;D cost item\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eCost structure role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development expense, 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.9B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eClinical and pipeline spending\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDICE Therapeutics acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.4B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePipeline acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVersanis Bio acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.93B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePipeline acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePOINT Biopharma Global acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.4B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePlatform acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSigilon Therapeutics acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$309.6M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePlatform acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eManufacturing expansion and validation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eEli Lilly and Company announced \u003cstrong\u003e$5.3B\u003c\/strong\u003e for a new manufacturing site in Lebanon, Indiana. That spend sits on top of validation work, equipment qualification, and scale-up costs that follow after construction starts.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$5.3B\u003c\/strong\u003e Lebanon, Indiana manufacturing project\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAcquisition and contingent consideration costs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eRecent acquisition consideration totals include \u003cstrong\u003e$3.2B\u003c\/strong\u003e for Morphic Holding, \u003cstrong\u003e$2.4B\u003c\/strong\u003e for DICE Therapeutics, \u003cstrong\u003e$1.93B\u003c\/strong\u003e for Versanis Bio, \u003cstrong\u003e$1.4B\u003c\/strong\u003e for POINT Biopharma Global, and \u003cstrong\u003e$309.6M\u003c\/strong\u003e for Sigilon Therapeutics.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eAcquisition\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eCost structure role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMorphic Holding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.2B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcquisition consideration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDICE Therapeutics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.4B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcquisition consideration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVersanis Bio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.93B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcquisition consideration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePOINT Biopharma Global\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.4B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcquisition consideration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSigilon Therapeutics\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$309.6M\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAcquisition consideration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eSG\u0026amp;A and product launches\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMarketing, selling and administrative expense was \u003cstrong\u003e$6.6B\u003c\/strong\u003e in 2023. That line carries commercial launch spending, sales force costs, medical affairs, and market access work.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$6.6B\u003c\/strong\u003e marketing, selling and administrative expense, 2023\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLitigation and legal defense costs\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSeparate annual legal-defense spend disclosed: \u003cstrong\u003e$0\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eCompanywide legal-defense cost is not presented as a separate annual line item in the disclosed operating expenses.\u003c\/p\u003e\u003ch2\u003eEli Lilly and Company - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$16.4 billion\u003c\/strong\u003e from Mounjaro and Zepbound in 2024 versus \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e total revenue equals \u003cstrong\u003e36.4%\u003c\/strong\u003e of Eli Lilly and Company revenue.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eRevenue stream\u003c\/th\u003e\n\u003cth\u003e2024 product sales\u003c\/th\u003e\n\u003cth\u003e2024 share of $45.0 billion revenue\u003c\/th\u003e\n\u003cth\u003eLate 2025 status\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMounjaro\u003c\/td\u003e\n\u003ctd\u003e$11.5 billion\u003c\/td\u003e\n\u003ctd\u003e25.6%\u003c\/td\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eZepbound\u003c\/td\u003e\n\u003ctd\u003e$4.9 billion\u003c\/td\u003e\n\u003ctd\u003e10.9%\u003c\/td\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKisunla\u003c\/td\u003e\n\u003ctd\u003e$21 million\u003c\/td\u003e\n\u003ctd\u003e0.05%\u003c\/td\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetevmo\u003c\/td\u003e\n\u003ctd\u003e$0.7 billion\u003c\/td\u003e\n\u003ctd\u003e1.6%\u003c\/td\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral obesity candidate\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003eNot commercialized\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eMounjaro product sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$11.5 billion\u003c\/strong\u003e in 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eZepbound product sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$4.9 billion\u003c\/strong\u003e in 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKisunla product sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$21 million\u003c\/strong\u003e in 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRetevmo product sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$0.7 billion\u003c\/strong\u003e in 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFoundayo oral obesity sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$0\u003c\/strong\u003e as of late 2025.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$11.5 billion\u003c\/strong\u003e from Mounjaro\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.9 billion\u003c\/strong\u003e from Zepbound\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$21 million\u003c\/strong\u003e from Kisunla\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$0.7 billion\u003c\/strong\u003e from Retevmo\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$0\u003c\/strong\u003e from the oral obesity candidate\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003e16.4 billion\u003c\/strong\u003e from Mounjaro and Zepbound versus \u003cstrong\u003e$45.0 billion\u003c\/strong\u003e total revenue equals \u003cstrong\u003e36.4%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e0.05%\u003c\/strong\u003e for Kisunla.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e1.6%\u003c\/strong\u003e for Retevmo.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e0%\u003c\/strong\u003e for the oral obesity candidate.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601609814165,"sku":"lly-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/lly-business-model-canvas.png?v=1740169488","url":"https:\/\/dcf-analysis.com\/products\/lly-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}